The Japanese Journal of Dermatology
Online ISSN : 1346-8146
Print ISSN : 0021-499X
ISSN-L : 0021-499X
Search
Advanced search
OR
Browse
Search
Volume 131, Issue 10
Displaying 1-6 of 6 articles from this issue
Show all abstracts
    • |<
    • <
    • 1
    • >
    • >|
Guidance
Seminar for Medical Education
Original Articles
  • Efficacy of Belimumab for Treatment of Cutaneous Manifestations of Systemic Lupus Erythematosus; A Report of Three Cases
    Manami Okuzawa, Yukari Zenke, Ryota Shibuya, Kyoko Tsumura, Toshiaki N ...
    2021Volume 131Issue 10 Pages 2287-2296
    Published: September 20, 2021
    Released on J-STAGE: September 21, 2021
    DOIhttps://doi.org/10.14924/dermatol.131.2287
    JOURNAL RESTRICTED ACCESS
    Show abstractHide abstract

    Cutaneous manifestations of systemic lupus erythematosus (SLE) are occasionally resistant to conventional treatment options.

    Belimumab is the first biological agent for the treatment of SLE, it was approved in 2017. We report three cases of SLE with refractory cutaneous manifestations successfully treated with belimumab.

    Case 1: A 27-year-old man developed multiple lupus erythematosus profundus lesions on his scalp, face, and trunk.

    Case 2: A 33-year-old woman had chilblain lupus erythematosus on her nose.

    Case 3: A 17-year-old female adolescent developed refractory butterfly-shaped erythema and multiple incomplete hair loss patches scattered on her scalp associated with erythema. All the patients received oral corticosteroids and immunosuppressants for SLE; however, none of them had an sufficient response. Belimumab was effective not only against systemic symptoms but also successful in treating the severe cutaneous manifestations of SLE; therefore, we could reduce the oral corticosteroid dosage. Based on these findings, we propose belimumab as an effective treatment option for refractory cutaneous manifestations of SLE.

    View full abstract
    Download PDF (2504K)
Erratum
    • |<
    • <
    • 1
    • >
    • >|
feedback
 Top